Collaboration to Identify Genomic Biomarkers

A collaborative agreement to identify and apply genomic biomarkers has been announced by Althea Technologies, Inc. (San Diego, CA, USA) and Expression Analysis, Inc. (EA, Durham, NC, USA).

EA and Althea will be offering a comprehensive "Signature Discovery Service” that will allow researchers and drug developers to progress from global to focused gene expression analysis, aiding the discovery and application of validated gene expression biomarkers for a targeted disease or drug activity. Both firms will contribute to the design, data mining and analysis, and data management of specialized studies that will take advantage of EA's expertise in the application of the GeneChip microarray technology of Affymetrix (Santa Clara, CA, USA) and Althea's proprietary express Profiling technology that allows for high throughput gene expression analysis.

"Through our alliance with Expression Analysis, we are able to provide a direct path from global gene expression profiling to identifying those focused sets of gene that are key to a research goal,” explained Dr. Francois Ferre, copresident and co-CEO of Althea Technologies. "Whether it is discovering disease classifiers, characterizing targets and pathways, evaluating lead compounds, or creating toxicological profiles, the two companies are now able to provide a compete analytical solution.”

Althea Technologies provides critical manufacturing and development services that supports researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. EA is a full-service microarray genetics testing and analysis organization dedicated to providing clients with high quality genomic processing and data analysis services, using Affymetrix GeneChip technology.




Related Links:
Althea Technologies
Expression Analysis, Inc.